Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Broker Notes
5 ASX 200 stocks that could negatively surprise during earnings season
Best Shares
6 ASX 200 shares that could benefit from a weak Australia Dollar
How to invest
I'd use Warren Buffett's methods to get rich and retire early with ASX shares
Investing Strategies
Are these ASX 200 'moat' stocks undervalued right now?
Share Market News
Here are the top 10 ASX 200 shares today
Healthcare Shares
Here's how the ASX 200 market sectors stacked up last week
How to invest
$20,000 invested in these ASX 200 shares 10 years ago is now worth…
Share Market News
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Market News
7 ASX 200 directors sell huge chunks of company shares
Healthcare Shares
Why is the Cochlear share price in the red today?
Share Market News
5 things to watch on the ASX 200 on Tuesday
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.